This report illustrates that PF is an ominous cutaneous sign of fulminant neonatal GBS septicemia. Childhood PF is often associated with meningococcaemia [1–3]. In the neonatal period group B streptococcus is the major cause of PF but gram negative organisms such as Escherichia coli and Enterobacter have been described [7–11].
Nolan et al reported two cases of PF associated with meningococcal and chickenpox, respectively, and reviewed various treatment modalities [1]. Protein C and antithrombin III have been given if these factors are deficient [1, 5]. In PF associated with meningococcemia and septic shock, Rivard et al described severe acquired protein C deficiency successfully treated with conventional therapy and high-volume plasma exchange as a source of protein C [2]. Many other therapies have been described in case reports that claimed to arrest the progression of neonatal PF, such as the use of heparin [8], Protein C [5, 12], Antithrombin III, recombinant tissue plasminogen activator (rtPA), epoprostenol (prostacyclin) [6], topical nitroglycerin, intravenous dextran, and plasmapheresis [1–13]. Nevertheless, there is no strong evidence in favor of one particular therapy due to the small number of cases.
One limitation of our case was that the coagulopathy was immediately treated empirically before the endogenous activities of the anticoagulant factors protein C, protein S, and Antithrombin III (AT III) were assessed. In case any of these factors are found to be affected, human protein C or recombinant human activated protein C may be considered, and protein C, protein S, and AT III genes should have been analyzed in the patient and her parents. There was no family history of coagulopathy and group B streptococcus was identified to be the pathogen, making syndromes of congenital anticoagulant factor deficiency unlikely in this patient.
Regardless of the pathogen, neonatal PF must be promptly recognized and aggressively treated in children [1–6]. Early goal-directed therapy provides significant benefits with respect to outcome in adult patients with severe sepsis and septic shock [14]. The therapy involves adjustments of cardiac preload, afterload, and contractility to balance oxygen delivery with oxygen demand. Guidelines were proposed through the Surviving Sepsis Campaign to improve outcome in septic patients [15]. They are difficult to apply routinely and validate in neonates. As Claessens et al has commented, attempts to apply all of the procedures recommended by the experts, despite the apparent pragmatism of those procedures, have varied widely; diagnosis may be problematic because of atypical or unspecific presentations, biomarkers are of little help at the start of treatment and are unspecific, supportive treatment often depends on local supply of resources, and specific devices are often absent for initial therapy and monitoring [15]. Resuscitation policy for septic shock in neonates generally includes prompt treatment of the underlying infection with broad spectrum antibiotics, replacement of fluids or blood for preload, appropriate usage of inotropes for cardiac contractility and afterload, support of oxygenation and ventilation with mechanical ventilation, and support of individual multi-organ system failure [16].
Despite full intensive care support, PF is often associated with multiple organ failure and high mortality in children [4]. PF has a reported mortality of 50 per cent secondary to multiple organ failure which commonly accompanies the syndrome and is associated with major long-term morbidity in those who survive [4]. In 3 cases of early neonatal PF, all the babies survived but had markedly compromised neurologic outcomes [7].
